Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other Non-Current Liabilities: 2014-2025

Historic Other Non-Current Liabilities for Gyre Therapeutics (GYRE) over the last 4 years, with Sep 2025 value amounting to $3.2 million.

  • Gyre Therapeutics' Other Non-Current Liabilities fell 70.04% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 70.04%. This contributed to the annual value of $10.6 million for FY2024, which is 39.46% down from last year.
  • Gyre Therapeutics' Other Non-Current Liabilities amounted to $3.2 million in Q3 2025, which was up 0.72% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Other Non-Current Liabilities registered a high of $17.6 million during Q4 2023, and its lowest value of $55,000 during Q4 2022.
  • In the last 3 years, Gyre Therapeutics' Other Non-Current Liabilities had a median value of $9.6 million in 2023 and averaged $8.3 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 31,821.82% in 2023, then crashed by 74.39% in 2025.
  • Gyre Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $55,000 in 2022, then skyrocketed by 31,821.82% to $17.6 million in 2023, then crashed by 39.46% to $10.6 million in 2024, then crashed by 70.04% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $3.2 million for Q2 2025, and $3.4 million during Q1 2025.